tucatinib
EGFR-sparing HER2 kinase inhibitor approved in met. HER2+ BC incl. w/ brain met. from optimization of known TKIs Mol. Cancer Ther., Apr. 1, 2020 Array / Cascadian Tx / Seattle Genetics
Molecules of the Month - April 2020
Molecules of the Month
- tucatinib
- S6821
- MRTX849
- BAY1161909
- ORN0829
- BMS-986251
- GSK2818713
- CPI-1612
- “Compound 19”
- AZD4205
- QPX7728
- “Compound 9”
- “Compound (P)-14″
- FT385